WHIPPANY, N.J., April 1, 2016 /PRNewswire/ -- Bayer will host an event for members of the bleeding disorders community, patients and their families during the Hemophilia Federation of America (HFA) Annual Symposium, which takes place from March 31 to April 2 in Las Vegas. The April 2 breakfast event will feature a keynote address from Dr. Mae Jemison, the first African-American woman astronaut in space, who will share her love of exploration, science education and growing up strong.
Also a physician, engineer and accomplished children's author, Dr. Jemison is Bayer's long-time ambassador and advocate for its award-winning "Making Science Make Sense" initiative, which advances science literacy across the United States through hands-on learning, public education, and employee volunteerism.
"I believe that all children are innately interested in science," said Dr. Jemison. "Frequently young people with chronic illnesses are even more likely to be engaged in and knowledgeable about science, as they gain an early command of concepts about their body and the environment in order to understand their disease and manage their health."
Dr. Jemison's talk will highlight the importance of science education, not just for students pursuing careers in science, but for all of us in our everyday lives.
"Bayer has a long legacy of commitment to science and education," said Dario Mirski, MD, Bayer's senior vice president of medical affairs for the Americas. "As a life sciences company, we are want to help develop the next generation of innovators to help us advance medical care long into the future."
The event will take place during HFA, on Saturday, April 2 from 7:00 to 9:00 a.m. at the JW Marriott, Las Vegas.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their lives. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Forward Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
PP-775-US-0163
Intended for U.S. media only
Logo - http://photos.prnewswire.com/prnh/20140312/NY79226LOGO
SOURCE Bayer Corporation